# Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

> **NCT00298350** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 278 (actual)

## Conditions studied

- HIV
- HIV-1
- Human Immunodeficiency Virus

## Interventions

- **DRUG:** GS-9137 - A Novel HIV-1 Integrase Inhibitor

## Key facts

- **NCT ID:** NCT00298350
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-06
- **Final completion:** 2007-07
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2008-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298350, "Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00298350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*